{"id":"curexcell","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Hemorrhage"},{"rate":"1-5%","effect":"Allergic reactions"},{"rate":"1-5%","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by dissolving blood clots through enzymatic degradation of fibrin. This process is crucial in treating conditions like ischemic stroke and pulmonary embolism.","oneSentence":"CureXcell is a recombinant human thrombolytic enzyme.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:09.085Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ischemic stroke"},{"name":"Pulmonary embolism"}]},"trialDetails":[{"nctId":"NCT01421966","phase":"PHASE3","title":"Evaluation of CureXcell® in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes","status":"COMPLETED","sponsor":"Macrocure Ltd.","startDate":"2011-08","conditions":"Lower Extremity Chronic Ulcers in Diabetics","enrollment":285},{"nctId":"NCT02130310","phase":"PHASE3","title":"Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers","status":"UNKNOWN","sponsor":"Macrocure Ltd.","startDate":"2014-05","conditions":"Chronic Venous Leg Ulcers","enrollment":252},{"nctId":"NCT01038986","phase":"","title":"A Post-marketing Observational Study of Cell Therapy for Chronic Wounds","status":"COMPLETED","sponsor":"Macrocure Ltd.","startDate":"2009-12","conditions":"Wounds","enrollment":70},{"nctId":"NCT01113307","phase":"","title":"The Use of CureXcellTM in a Community Setting for the Treatment of Hard to Heal Wounds","status":"COMPLETED","sponsor":"Macrocure Ltd.","startDate":"2010-05","conditions":"Wounds","enrollment":131}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CureXcell","genericName":"CureXcell","companyName":"Macrocure Ltd.","companyId":"macrocure-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"CureXcell is a recombinant human thrombolytic enzyme. Used for Ischemic stroke, Pulmonary embolism.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}